GLP-1 receptor agonists cut the risk of lung cancer recurrence or death by roughly 59% in overweight patients, and appear to enhance how well immunotherapy works.
59%Reduction in hazard of lung cancer recurrence or death after surgery for overweight/obese patients on GLP-1 drugs (HR 0.41)
What the researchers found
GLP-1 receptor agonist use was associated with a 59% reduction in the hazard of recurrence or death after lung cancer surgery (HR 0.41), and a 69% reduction in the hazard of progression when added to immunotherapy, in overweight and obese patients.
Why it matters
Obesity worsens lung cancer prognosis, and immunotherapy is only partially effective. If GLP-1 drugs can reprogram the tumor immune microenvironment in obese patients, they could become an inexpensive add-on to existing cancer treatment—leveraging a medication millions already take.
The numbers in context
- Surgical cohort: 1,177 patients, 71 GLP-1 users; recurrence HR 0.41 (95% CI 0.16-1.04, p=0.026)
- Immunotherapy cohort: 300 patients, 10 GLP-1 users; overall survival HR 0.41 (p=0.027); progression-free survival HR 0.31 (p=0.019)
- Mouse studies: tumor reduction in obese mice only
How the study worked
Propensity-score-matched retrospective analysis of two clinical cohorts (surgical resection n=1,177; immunotherapy n=300) plus mechanistic mouse model experiments in obese and normal-weight mice.
Who was studied
Two cohorts of overweight/obese NSCLC patients: 1,177 post-surgery (71 GLP-1 users) and 300 on immunotherapy (10 GLP-1 users). Plus obese and normal-weight mouse models.
What this study cannot tell us
Small number of GLP-1 users in each cohort (especially only 10 in the immunotherapy group) limits statistical power. Retrospective design introduces potential unmeasured confounders. Mouse results may not translate directly to humans. Obesity definition varies.
How to read the evidence
Rated moderate because both clinical arms are retrospective and involve very small GLP-1-user subgroups; propensity matching reduces but does not eliminate confounding.
When this study was published
Published in 2025 in JCI Insight; clinical data drawn from existing hospital records across multiple time periods.
The bigger picture
This adds to a growing body of evidence showing GLP-1 drugs reduce the incidence of several cancers. The obesity-restricted effect seen in mice suggests the mechanism is metabolic and immune—relevant specifically to obesity-driven tumor biology—rather than a direct anti-cancer drug effect.
Questions still open
- Would prospective randomized trials confirm GLP-1 drugs as a cancer treatment adjunct?
- Do non-obese lung cancer patients receive any benefit from GLP-1 drugs?
- Which specific GLP-1 drug (or dose) produces the strongest immune modulation in tumors?
Common questions
Does this mean GLP-1 drugs treat cancer?
Should I start a GLP-1 drug to prevent lung cancer recurrence?
Read the original research
Glucagon-like peptide-1 receptor agonism improves lung cancer outcomes and tumor growth control.
JCI insight, 10(19)
Citation
Pachimatla, Akhil Goud; Fitzgerald, Bailey; Ogidigo, Joyce; Bhatia, Meera; Smith, Randall J; Ratnakaram, Kalyan; Kalvapudi, Sukumar; Vedire, Yeshwanth; Washington, Deschana; Vethanayagam Rr, Robert; Hsiao, Hua-Hsin; Rosario, Spencer; Sanghvi, Viraj R; Barbi, Joseph; Yendamuri, Sai. (2025). Glucagon-like peptide-1 receptor agonism improves lung cancer outcomes and tumor growth control.. JCI insight, 10(19). https://doi.org/10.1172/jci.insight.195484